PepGen (PEPG) Competitors $1.37 -0.07 (-4.86%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.31 -0.06 (-4.38%) As of 02/21/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PEPG vs. IKT, GLSI, IPHA, FATE, CKPT, SLDB, MGNX, OGI, NKTX, and ADCTShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), Innate Pharma (IPHA), Fate Therapeutics (FATE), Checkpoint Therapeutics (CKPT), Solid Biosciences (SLDB), MacroGenics (MGNX), Organigram (OGI), Nkarta (NKTX), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Inhibikase Therapeutics Greenwich LifeSciences Innate Pharma Fate Therapeutics Checkpoint Therapeutics Solid Biosciences MacroGenics Organigram Nkarta ADC Therapeutics PepGen (NASDAQ:PEPG) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability. Which has better valuation & earnings, PEPG or IKT? Inhibikase Therapeutics has higher revenue and earnings than PepGen. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$2.98-0.46Inhibikase Therapeutics$260K792.30-$19.03M-$2.67-1.11 Is PEPG or IKT more profitable? PepGen's return on equity of -60.17% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -60.17% -48.88% Inhibikase Therapeutics N/A -350.63%-201.82% Do insiders & institutionals have more ownership in PEPG or IKT? 58.0% of PepGen shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 4.6% of PepGen shares are owned by insiders. Comparatively, 4.6% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate PEPG or IKT? PepGen currently has a consensus price target of $10.33, suggesting a potential upside of 654.26%. Inhibikase Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 118.86%. Given PepGen's higher possible upside, research analysts plainly believe PepGen is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, PEPG or IKT? PepGen has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Does the media refer more to PEPG or IKT? In the previous week, Inhibikase Therapeutics had 8 more articles in the media than PepGen. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 0 mentions for PepGen. Inhibikase Therapeutics' average media sentiment score of 0.64 beat PepGen's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment PepGen Neutral Inhibikase Therapeutics Positive Does the MarketBeat Community prefer PEPG or IKT? PepGen received 10 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. However, 81.82% of users gave Inhibikase Therapeutics an outperform vote while only 79.17% of users gave PepGen an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes1979.17% Underperform Votes520.83% Inhibikase TherapeuticsOutperform Votes981.82% Underperform Votes218.18% SummaryPepGen beats Inhibikase Therapeutics on 9 of the 16 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.94M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.465.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.306.717.644.62Net Income-$78.63M$138.33M$3.18B$245.85M7 Day Performance7.87%-2.61%-1.99%-2.68%1 Month Performance-30.81%-2.32%-0.42%-2.19%1 Year Performance-90.18%-5.31%16.51%12.84% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.4295 of 5 stars$1.37-4.9%$10.33+654.3%-90.0%$46.94MN/A-0.4630Gap UpIKTInhibikase Therapeutics1.6284 of 5 stars$2.35+5.4%$6.50+176.6%+33.8%$163.00M$260,000.00-0.886GLSIGreenwich LifeSciences2.0796 of 5 stars$12.38+0.7%$38.00+206.9%-9.2%$162.80MN/A-15.473IPHAInnate Pharma3.0108 of 5 stars$1.94-0.5%$11.50+492.8%-7.8%$162.63M$66.71M0.00220News CoverageGap UpFATEFate Therapeutics4.203 of 5 stars$1.42+11.8%$6.75+375.4%-79.2%$161.72M$63.53M-0.86550Gap UpHigh Trading VolumeCKPTCheckpoint Therapeutics3.1818 of 5 stars$3.31-4.3%$12.00+262.5%+63.0%$161.63M$100,000.00-1.8010SLDBSolid Biosciences4.0798 of 5 stars$4.03+2.3%$15.30+279.7%-42.4%$161.04M$8.09M-1.33100Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeMGNXMacroGenics3.5751 of 5 stars$2.56+4.1%$7.63+197.9%-83.8%$160.67M$58.75M-1.62430News CoverageOGIOrganigram0.7394 of 5 stars$1.27-5.9%N/A-34.8%$160.22M$117.47M-3.34860High Trading VolumeNKTXNkarta2.6181 of 5 stars$2.21+4.2%$15.00+578.7%-78.5%$155.96MN/A-1.18140ADCTADC Therapeutics2.8839 of 5 stars$1.61-0.3%$8.00+398.4%-65.1%$155.19M$69.56M-0.67310Short Interest ↓ Related Companies and Tools Related Companies Inhibikase Therapeutics Alternatives Greenwich LifeSciences Alternatives Innate Pharma Alternatives Fate Therapeutics Alternatives Checkpoint Therapeutics Alternatives Solid Biosciences Alternatives MacroGenics Alternatives Organigram Alternatives Nkarta Alternatives ADC Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PEPG) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PEPG Stock Alerts